MTOR and type 2 diabetes mellitus: Studies have shown that Empagliflozin, an SGLT-2 inhibitor, in addition to its significant hypoglycemic effect, can also enhance autophagy in liver macrophages via the AMPK/mTOR signaling pathway and further inhibit the IL-17/IL-23 axis-mediated inflammatory response, thereby significantly ameliorating liver injury in mice with T2DM combined with NAFLD (134).